# Frederique Vegran

List of Publications by Year
in descending order



| 62 | 5,853 | 172457 | 138484 |
|---|---|---|---|
| papers | citations | 29 h-index | 58 g-index |

| 67 | 67 | 67 | 10300 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. Journal of Clinical Investigation, 2008, 118, 3930-42. | 8.2 | 1,225 |
| 2 | Lactate Influx through the Endothelial Cell Monocarboxylate Transporter MCT1 Supports an NF-ÎºB/IL-8 Pathway that Drives Tumor Angiogenesis. Cancer Research, 2011, 71, 2550-2560. | 0.9 | 637 |
| 3 | Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nature Medicine, 2013, 19, 57-64. | 30.7 | 634 |
| 4 | Targeting the Lactate Transporter MCT1 in Endothelial Cells Inhibits Lactate-Induced HIF-1 Activation and Tumor Angiogenesis. PLoS ONE, 2012, 7, e33418. | 2.5 | 412 |
| 5 | The receptor NLRP3 is a transcriptional regulator of TH2 differentiation. Nature Immunology, 2015, 16, 859-870. | 14.5 | 312 |
| 6 | Stat3 and Gfi-1 Transcription Factors Control Th17 Cell Immunosuppressive Activity via the Regulation of Ectonucleotidase Expression. Immunity, 2012, 36, 362-373. | 14.3 | 275 |
| 7 | Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOXâ€“Bevacizumab Drug Treatment Regimen. Cancer Research, 2016, 76, 5241-5252. | 0.9 | 203 |
| 8 | The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells. Nature Immunology, 2014, 15, 758-766. | 14.5 | 187 |
| 9 | Regulation of Monocarboxylate Transporter MCT1 Expression by p53 Mediates Inward and Outward Lactate Fluxes in Tumors. Cancer Research, 2012, 72, 939-948. | 0.9 | 172 |
| 10 | PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer. OncoImmunology, 2018, 7, e1433981. | 4.6 | 167 |
| 11 | STAT3 activation. Jak-stat, 2013, 2, e23010. | 2.2 | 159 |
| 12 | Liver X receptor Î² activation induces pyroptosis of human and murine colon cancer cells. Cell Death and Differentiation, 2014, 21, 1914-1924. | 11.2 | 127 |
| 13 | Bleomycin Exerts Ambivalent Antitumor Immune Effect by Triggering Both Immunogenic Cell Death and Proliferation of Regulatory T Cells. PLoS ONE, 2013, 8, e65181. | 2.5 | 103 |
| 14 | Dacarbazine-Mediated Upregulation of NKG2D Ligands on Tumor Cells Activates NK and CD8 T Cells and Restrains Melanoma Growth. Journal of Investigative Dermatology, 2013, 133, 499-508. | 0.7 | 75 |
| 15 | Overexpression of Caspase-3s Splice Variant in Locally Advanced Breast Carcinoma Is Associated with Poor Response to Neoadjuvant Chemotherapy. Clinical Cancer Research, 2006, 12, 5794-5800. | 7.0 | 67 |
| 16 | Restoration of Antitumor Immunity Through Selective Inhibition of Myeloid Derived Suppressor Cells by Anticancer Therapies. Current Molecular Medicine, 2011, 11, 365-372. | 1.3 | 64 |
| 17 | TH9 cells in anti-tumor immunity. Seminars in Immunopathology, 2017, 39, 39-46. | 6.1 | 63 |
| 18 | Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer. Oncogene, 2007, 26, 290-297. | 5.9 | 60 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Transcriptional regulation of the survivin gene. Molecular Biology Reports, 2014, 41, 233-240. | 2.3 | 59 |
| 20 | Th9 Cells: A Novel CD4 T-cell Subset in the Immune War against Cancer. Cancer Research, 2015, 75, 475-479. | 0.9 | 56 |
| 21 | Cleaved Caspase-3 Transcriptionally Regulates Angiogenesis-Promoting Chemotherapy Resistance. Cancer Research, 2019, 79, 5958-5970. | 0.9 | 55 |
| 22 | SOCS3 Transactivation by PPARÎ³ Prevents IL-17â€“Driven Cancer Growth. Cancer Research, 2013, 73, 3578-3590. | 0.9 | 51 |
| 23 | Recruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses. Nature Immunology, 2022, 23, 262-274. | 14.5 | 47 |
| 24 | IRF8-dependent molecular complexes control the Th9 transcriptional program. Nature Communications, 2017, 8, 2085. | 12.8 | 43 |
| 25 | The transcription factor GATA-1 is overexpressed in breast carcinomas and contributes to survivin upregulation via a promoter polymorphism. Oncogene, 2010, 29, 2577-2584. | 5.9 | 42 |
| 26 | The expression of BIRC5 is correlated with loss of specific chromosomal regions in breast carcinomas. Genes Chromosomes and Cancer, 2008, 47, 299-308. | 2.8 | 40 |
| 27 | Human ectonucleotidase-expressing CD25<sup>high</sup>Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions. OncoImmunology, 2016, 5, e1055444. | 4.6 | 39 |
| 28 | The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?. Oncotarget, 2017, 8, 1957-1971. | 1.8 | 38 |
| 29 | Only Missense Mutations Affecting the DNA Binding Domain of P53 Influence Outcomes in Patients with Breast Carcinoma. PLoS ONE, 2013, 8, e55103. | 2.5 | 36 |
| 30 | A Short Caspase-3 Isoform Inhibits Chemotherapy-Induced Apoptosis by Blocking Apoptosome Assembly. PLoS ONE, 2011, 6, e29058. | 2.5 | 33 |
| 31 | Role of Cytokines and Chemokines in Angiogenesis in a Tumor Context. Cancers, 2022, 14, 2446. | 3.7 | 32 |
| 32 | Gene expression profile and response to trastuzumabâ€“docetaxel-based treatment in breast carcinoma. British Journal of Cancer, 2009, 101, 1357-1364. | 6.4 | 27 |
| 33 | Apoptosis gene signature of Survivin and its splice variant expression in breast carcinoma. Endocrine-Related Cancer, 2011, 18, 783-792. | 3.1 | 26 |
| 34 | Survivin-3B Potentiates Immune Escape in Cancer but Also Inhibits the Toxicity of Cancer Chemotherapy. Cancer Research, 2013, 73, 5391-5401. | 0.9 | 23 |
| 35 | Predictive value of survivin alternative transcript expression in locally advanced breast cancer patients treated with neoadjuvant chemotherapy. International Journal of Molecular Medicine, 2009, 23, 285-91. | 4.0 | 22 |
| 36 | CD4 T cell-intrinsic STING signaling controls the differentiation and effector functions of T<sub>H</sub>1 and T<sub>H</sub>9 cells. , 2022, 10, e003459. | | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Modulation of CD4 T Cell Response According to Tumor Cytokine Microenvironment. Cancers, 2021, 13, 373. | 3.7 | 18 |
| 38 | Distinct expression of Survivin splice variants in breast carcinomas. International Journal of Oncology, 2005, 27, 1151-7. | 3.3 | 18 |
| 39 | Impact of Lipid Metabolism on Antitumor Immune Response. Cancers, 2022, 14, 1850. | 3.7 | 18 |
| 40 | Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein. World Journal of Gastroenterology, 2016, 22, 10680. | 3.3 | 15 |
| 41 | Alternative Splicing in Cancer and Immune Cells. Cancers, 2022, 14, 1726. | 3.7 | 15 |
| 42 | Regulation of T cell antitumor immune response by tumor induced metabolic stress. Cell Stress, 2019, 3, 9-18. | 3.2 | 14 |
| 43 | Distinct expression of Survivin splice variants in breast carcinomas. International Journal of Oncology, 2005, 27, 1151. | 3.3 | 13 |
| 44 | Predictive value of survivin alternative transcript expression in locally advanced breast cancer patients treated with neoadjuvant chemotherapy. International Journal of Molecular Medicine, 1998, 23, 285. | 4.0 | 12 |
| 45 | Transcriptional Programs Underlying Cd4 T Cell Differentiation and Functions. International Review of Cell and Molecular Biology, 2018, 341, 1-61. | 3.2 | 12 |
| 46 | Survivin-3B promotes chemoresistance and immune escape by inhibiting caspase-8 and -6 in cancer cells. OncoImmunology, 2013, 2, e26328. | 4.6 | 10 |
| 47 | Transcriptome analysis of TH2 CD4+ T cells differentiated from wild-type and NLRP3KO mice. Genomics Data, 2015, 5, 314-315. | 1.3 | 10 |
| 48 | Socs3 induction by PPARÎ³ restrains cancer-promoting inflammation. Cell Cycle, 2013, 12, 2157-2158. | 2.6 | 8 |
| 49 | The Tumor Microenvironment Impairs Th1 IFNÎ³ Secretion through Alternative Splicing Modifications of Irf1 Pre-mRNA. Cancer Immunology Research, 2021, 9, 324-336. | 3.4 | 8 |
| 50 | Variations in Gene Expression and Response to Neoadjuvant Chemotherapy in Breast Carcinoma. Cancer Investigation, 2009, 27, 521-528. | 1.3 | 6 |
| 51 | Lactate-Induced IL-8 Pathway in Endothelial Cellsâ€”Response: Figure 1.. Cancer Research, 2012, 72, 1903-1904. | 0.9 | 6 |
| 52 | Transcriptional expression of 8 genes predicts pathological response to first-line docetaxelâ€‰+â€‰trastuzumab-based neoadjuvant chemotherapy. BMC Cancer, 2015, 15, 169. | 2.6 | 5 |
| 53 | Patterns of loss of heterozygosity in breast carcinoma during neoadjuvant chemotherapy. International Journal of Oncology, 0, , . | 3.3 | 5 |
| 54 | <scp>NLRP6</scp> negatively regulates type 2 immune responses in mice. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3320-3336. | 5.7 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Protein Kinase Inhibitor-Mediated Immunoprophylactic and Immunotherapeutic Control of Colon Cancer. Frontiers in Immunology, 2022, 13, 875764. | 4.8 | 2 |
| 56 | Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects. Cancer Immunology Research, 2022, 10, 900-916. | 3.4 | 2 |
| 57 | Proximity Ligation Assay (PLA) Protocol Using Duolink® for T Cells. Bio-protocol, 2016, 6, . | 0.4 | 1 |
| 58 | The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?. Journal of Clinical Oncology, 2016, 34, e13116-e13116. | 1.6 | 1 |
| 59 | Transcription Factor Binding Studies in CD4+ T Cells: siRNA Transfection, Chromatin Immunoprecipitation, and Liquid Luminescent DNA Precipitation Assay. Methods in Molecular Biology, 2017, 1585, 167-177. | 0.9 | 0 |
| 60 | O28 Importance of pro-inflammatory immune lymphocyte Th17 in antitumoral properties of resveratrol, a polyphenol of wine. Biochemical Pharmacology, 2017, 139, 118-119. | 4.4 | 0 |
| 61 | Role of IL-17 and IL-17 Family Cytokines on Tumor Development. , 2013, , 219-230. | | 0 |
| 62 | Liquid Luminescent DNA-precipitation Assay. Bio-protocol, 2016, 6, . | 0.4 | 0 |